Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00842335 · ClinicalTrials.gov registry record · Phase 1

A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Jubilant Innovation.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target
1
Study location

NCT00842335 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Jubilant Innovation. The registered enrollment target is 18 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00842335, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Jubilant Innovation.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study, the first clinical trial of JI-101, is to determine the maximum tolerated dose of JI-101 when given orally to patients with solid tumors. Safety, tolerability, pharmacokinetics, pharmacodynamics, and the effects of the drug on tumor metabolism will also be studied. JI-101 is an inhibitor of new blood vessel growth that may provide benefit to patients with solid tumors that have failed standard therapeutic regimens.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG JI-101

Study Locations (1)

Arizona

  • Premiere Oncology of Arizona - Scottsdale

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2009-02
Est. Completion 2012-01
Phase Phase 1

Sponsor

Jubilant Innovation

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00842335

The ClinicalTrials.gov registry entry for NCT00842335 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (91% lower). The listed sponsor is Jubilant Innovation, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which JI-101 is the first listed.

NCT00842335 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT00842335 about?

NCT00842335 is a clinical study titled "A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors". The purpose of this study, the first clinical trial of JI-101, is to determine the maximum tolerated dose of JI-101 when given orally to patients with solid tumors. Safety, tolerability, pharmacokinetics, pharmacodynamics, and the effects of the drug on tumor metabolism will also be studied. JI-101 ...

What is the current status of trial NCT00842335?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2009-02. Estimated completion is 2012-01.

What conditions does trial NCT00842335 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT00842335?

The interventions under investigation include: JI-101 (DRUG).

Who is sponsoring clinical trial NCT00842335?

This trial is sponsored by Jubilant Innovation, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00842335 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.